Compare Stocks: ENTX, ZBIO, NTLA, and NUVB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$2.49 -6.0%	$2.90	$0.91 ▼ $4.20	$433.06M	1.4	1.01 million shs	754,970 shs
NTLA Intellia Therapeutics	$11.91 -5.3%	$12.26	$7.95 ▼ $28.25	$1.67B	1.8	5.20 million shs	5.17 million shs
NUVB Nuvation Bio	$4.73 -3.6%	$6.16	$3.36 ▼ $9.75	$1.66B	1.61	5.54 million shs	7.61 million shs
ZBIO Zenas BioPharma	$25.16 -4.7%	$30.71	$13.50 ▼ $44.60	$1.64B	-0.9	814,280 shs	519,650 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	-0.38%	+1.15%	-6.69%	+63.58%	0.00%
NTLA Intellia Therapeutics	-3.75%	-1.33%	+7.16%	-5.41%	-48.69%
NUVB Nuvation Bio	-2.16%	-1.37%	-19.79%	-16.79%	+31.29%
ZBIO Zenas BioPharma	-3.15%	-5.14%	-15.17%	-8.27%	-0.71%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ENTX Entera Bio	$2.49 -6.0%	$2.90	$0.91 ▼ $4.20	$433.06M	1.4	1.01 million shs	754,970 shs
NTLA Intellia Therapeutics	$11.91 -5.3%	$12.26	$7.95 ▼ $28.25	$1.67B	1.8	5.20 million shs	5.17 million shs
NUVB Nuvation Bio	$4.73 -3.6%	$6.16	$3.36 ▼ $9.75	$1.66B	1.61	5.54 million shs	7.61 million shs
ZBIO Zenas BioPharma	$25.16 -4.7%	$30.71	$13.50 ▼ $44.60	$1.64B	-0.9	814,280 shs	519,650 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ENTX Entera Bio	-0.38%	+1.15%	-6.69%	+63.58%	0.00%
NTLA Intellia Therapeutics	-3.75%	-1.33%	+7.16%	-5.41%	-48.69%
NUVB Nuvation Bio	-2.16%	-1.37%	-19.79%	-16.79%	+31.29%
ZBIO Zenas BioPharma	-3.15%	-5.14%	-15.17%	-8.27%	-0.71%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ENTX Entera Bio	2.83	Moderate Buy	$9.60	285.54% Upside
NTLA Intellia Therapeutics	2.26	Hold	$20.72	73.95% Upside
NUVB Nuvation Bio	2.67	Moderate Buy	$13.22	179.84% Upside
ZBIO Zenas BioPharma	2.56	Moderate Buy	$46.71	85.67% Upside

Current Analyst Ratings Breakdown

Latest ENTX, ZBIO, NTLA, and NUVB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	ZBIO Zenas BioPharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$44.00
10/6/2026	ZBIO Zenas BioPharma	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/6/2026	NTLA Intellia Therapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Overweight ➝ Underweight	$8.00
10/6/2026	NTLA Intellia Therapeutics	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Underweight	$8.00
9/30/2026	ZBIO Zenas BioPharma	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$41.00 ➝ $48.00
9/30/2026	ZBIO Zenas BioPharma	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$55.00
9/30/2026	NUVB Nuvation Bio	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Market Outperform ➝ Buy	$12.00
9/30/2026	ZBIO Zenas BioPharma	Wedbush Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$45.00
9/30/2026	ZBIO Zenas BioPharma	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$44.00
9/24/2026	ENTX Entera Bio	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$11.00
9/24/2026	ENTX Entera Bio	Guggenheim Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong-Buy

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ENTX Entera Bio	$40K	10,826.52	N/A	N/A	$0.29 per share	8.59
NTLA Intellia Therapeutics	$67.67M	24.66	N/A	N/A	$5.80 per share	2.05
NUVB Nuvation Bio	$62.90M	26.38	N/A	N/A	$0.88 per share	5.37
ZBIO Zenas BioPharma	$10M	163.99	N/A	N/A	$4.51 per share	5.58

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ENTX Entera Bio	-$11.44M	-$0.35	N/A	N/A	N/A	N/A	-147.19%	-103.22%	11/13/2026 (Estimated)
NTLA Intellia Therapeutics	-$412.69M	-$3.36	N/A	N/A	N/A	-672.16%	-57.79%	-47.29%	11/5/2026 (Estimated)
NUVB Nuvation Bio	-$204.63M	-$0.44	N/A	N/A	N/A	-88.18%	-46.59%	-22.01%	11/2/2026 (Estimated)
ZBIO Zenas BioPharma	-$377.74M	-$8.99	N/A	N/A	N/A	N/A	-122.45%	-58.04%	11/12/2026 (Estimated)

Latest ENTX, ZBIO, NTLA, and NUVB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	NTLA Intellia Therapeutics	-$0.7982	N/A	N/A	N/A	$9.74 million	N/A
11/2/2026	Q3 2026	NUVB Nuvation Bio	-$0.1221	N/A	N/A	N/A	$34.81 million	N/A
8/13/2026	Q2 2026	ZBIO Zenas BioPharma	-$1.12	-$1.77	-$0.65	-$1.77	$15.00 million	$1.00 million
8/7/2026	Q2 2026	ENTX Entera Bio	-$0.08	-$0.14	-$0.06	-$0.14	N/A	N/A
8/6/2026	Q2 2026	NTLA Intellia Therapeutics	-$0.7993	-$0.80	-$0.0007	-$0.80	$12.98 million	$7.66 million
8/6/2026	Q2 2026	NUVB Nuvation Bio	-$0.1417	-$0.15	-$0.0083	-$0.18	$27.03 million	$31.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A
NUVB Nuvation Bio	N/A	N/A	N/A	N/A	N/A
ZBIO Zenas BioPharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ENTX Entera Bio	N/A	8.98	8.98
NTLA Intellia Therapeutics	N/A	6.65	6.65
NUVB Nuvation Bio	0.96	8.37	8.14
ZBIO Zenas BioPharma	1.57	9.93	9.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ENTX Entera Bio	14.11%
NTLA Intellia Therapeutics	88.77%
NUVB Nuvation Bio	61.67%
ZBIO Zenas BioPharma	N/A

Insider Ownership

Company	Insider Ownership
ENTX Entera Bio	10.57%
NTLA Intellia Therapeutics	3.50%
NUVB Nuvation Bio	30.11%
ZBIO Zenas BioPharma	22.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ENTX Entera Bio	21	173.92 million	155.54 million	Optionable
NTLA Intellia Therapeutics	377	140.13 million	135.22 million	Optionable
NUVB Nuvation Bio	305	351.12 million	245.40 million	Optionable
ZBIO Zenas BioPharma	167	65.18 million	50.84 million	N/A

ENTX, ZBIO, NTLA, and NUVB Headlines

Recent News About These Companies

Zenas BioPharma's (ZBIO) "Buy" Rating Reaffirmed at HC Wainwright

October 13 at 8:05 AM | marketbeat.com

Zenas BioPharma (ZBIO) Is Down 5.1% After New Phase 3 Obexelimab IgG4-RD Data Release

October 13 at 7:29 AM | uk.finance.yahoo.com

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

October 12 at 7:45 AM | markets.businessinsider.com

Head-To-Head Review: MacroGenics (NASDAQ:MGNX) vs. Zenas BioPharma (NASDAQ:ZBIO)

October 12 at 5:14 AM | americanbankingnews.com

Zenas BioPharma, Inc. (ZBIO) - What Are Researchers Saying About This Stock?

October 12 at 2:15 AM | americanbankingnews.com

Zenas BioPharma, Inc. (ZBIO) - What Are Analysts Thinking About This Stock?

October 12 at 2:13 AM | marketbeat.com

Zenas Biopharma Inc (ZBIO)

October 10 at 3:31 AM | investing.com

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis

October 8, 2026 | marketscreener.comM

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis

October 8, 2026 | marketscreener.comM

Zenas BioPharma (NASDAQ:ZBIO) Shares Down 6.2% - Time to Sell?

October 8, 2026 | marketbeat.com

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and ...

October 7, 2026 | markets.businessinsider.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Jumps 3.3% - Should You Buy?

October 7, 2026 | marketbeat.com

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

October 7, 2026 | globenewswire.com

Zenas BioPharma to Host Virtual R&D Event on October 27, 2026

October 6, 2026 | quiverquant.comQ

Zenas BioPharma to Host Virtual R&D Event

October 6, 2026 | globenewswire.com

Zenas BioPharma: Obexelimab Is Being Graded On The Wrong Curve

October 5, 2026 | seekingalpha.com

Zenas BioPharma (NASDAQ:ZBIO) Earns "Outperform" Rating from Wedbush

October 2, 2026 | americanbankingnews.com

HC Wainwright Reaffirms "Buy" Rating for Zenas BioPharma (NASDAQ:ZBIO)

October 2, 2026 | americanbankingnews.com

Zenas BioPharma (NASDAQ:ZBIO) Stock Price Up 7.1% - Still a Buy?

October 1, 2026 | marketbeat.com

Zenas BioPharma's Obexelimab Faces Larger IgG4-RD Opportunity, Wedbush Says

September 30, 2026 | marketscreener.comM

Wedbush Reaffirms Outperform Rating for Zenas BioPharma (NASDAQ:ZBIO)

September 30, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, ZBIO, NTLA, and NUVB Company Descriptions

Entera Bio NASDAQ:ENTX

$2.49 -0.16 (-6.04%)

Closing price 04:00 PM Eastern

Extended Trading

$2.50 +0.00 (+0.20%)

As of 04:25 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Intellia Therapeutics NASDAQ:NTLA

$11.91 -0.67 (-5.33%)

Closing price 04:00 PM Eastern

Extended Trading

$12.02 +0.12 (+0.97%)

As of 05:11 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Nuvation Bio NYSE:NUVB

$4.72 -0.18 (-3.57%)

Closing price 03:59 PM Eastern

Extended Trading

$4.73 +0.01 (+0.11%)

As of 05:10 PM Eastern

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.

Zenas BioPharma NASDAQ:ZBIO

$25.16 -1.24 (-4.70%)

Closing price 04:00 PM Eastern

Extended Trading

$25.28 +0.11 (+0.46%)

As of 04:37 PM Eastern

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTX, ZBIO, NTLA, and NUVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTX, ZBIO, NTLA, and NUVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTX, ZBIO, NTLA, and NUVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, ZBIO, NTLA, and NUVB Company Descriptions

Entera Bio NASDAQ:ENTX

Intellia Therapeutics NASDAQ:NTLA

Nuvation Bio NYSE:NUVB

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENTX, ZBIO, NTLA, and NUVB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENTX, ZBIO, NTLA, and NUVB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENTX, ZBIO, NTLA, and NUVB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENTX, ZBIO, NTLA, and NUVB Company Descriptions

Entera Bio NASDAQ:ENTX

Intellia Therapeutics NASDAQ:NTLA

Nuvation Bio NYSE:NUVB

Zenas BioPharma NASDAQ:ZBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools